Patent application number | Description | Published |
20080199527 | Enteric Coated Azithromycin Multiparticulates - A pharmaceutical composition is disclosed which comprises multiparticulates wherein said multiparticulates further comprise an azithromycin core and an enteric coating disposed upon said azithromycin core. | 08-21-2008 |
20080262107 | Pharmaceutical Compositions With Enhanced Performance - Disclosed are polymers of hydroxypropyl methyl cellulose acetate succinate (HPMCAS) and hydroxypropyl methyl cellulose acetate (HPMCA) with unique degrees of substitution of hydroxypropoxy, methoxy, acetyl, and succinoyl groups. When used in making compositions comprising a low-solubility drug and such polymers, the polymers provide enhanced aqueous concentrations and/or improved physical stability. | 10-23-2008 |
20080292707 | Pharmaceutical Compositions of Adsorbates of Amorphous Drug - Pharmaceutical compositions comprise a low-solubility drug adsorbed onto a high surface area substrate to form an adsorbate. The compositions in some embodiments include a concentration-enhancing polymer. | 11-27-2008 |
20080293801 | Solid Amorphous Dispersions of An Mtp Inhibitor For Treatment of Obesity - A composition comprises a solid amorphous dispersion comprising (S)—N-{2-[benzyl(methyl)amino]-2-oxo-1-phenylethyl}-methyl-5-[4′-(trifluoromethyl)[1,1′-biphenyl]-2-carboxamido]-1H-indole-2-carboxamide and a polymer. | 11-27-2008 |
20080299188 | CONTROLLED RELEASE DOSAGE FORMS COMBINING IMMEDIATE RELEASE AND SUSTAINTED RELEASE OF LOW-SOLUBILITY DRUG - A controlled release dosage form comprises an immediate release portion and an enteric coated sustained release core. | 12-04-2008 |
20080317851 | IMMEDIATE RELEASE DOSAGE FORMS CONTAINING SOLID DRUG DISBURSIONS - High loading immediate release dosage forms containing at least 30 wt % of a solid drug dispersion, at least 5 wt % of a disintegrant and a porosigen are disclosed that exhibit excellent strength and aqueous solubility. | 12-25-2008 |
20090011024 | Pharmaceutical compositions of dispersions of amorphous drugs mixed with polymers - A pharmaceutical composition comprises a dispersion comprising a low-solubility drug and a matrix combined with a concentration-enhancing polymer. At least a major portion of the drug is amorphous in the dispersion. The compositions improve the stability of the drug in the dispersion, and/or the concentration of drug in a use environment. | 01-08-2009 |
20090142404 | PHARMACEUTICAL DOSAGE FORMS COMPRISING A LOW-SOLUBILITY DRUG AND A POLYMER - A dosage form comprises a low-solubility drug, and a precipitation-inhibiting polymer. The drug is in a solubility-improved form and in the form of particles at least partially coated with the precipitation-inhibiting polymer. Exemplified low-solubility drugs are ziprasidone and sildenafil. Exemplified precipitation-inhibiting polymer is HPMCAS. | 06-04-2009 |
20100215747 | NANOPARTICLES COMPRISING IONIZABLE, POORLY WATER SOLUBLE CELLULOSIC POLYMERS - A pharmaceutical composition comprises nanoparticles comprising ionizable, poorly water soluble cellulosic polymers. | 08-26-2010 |
20110182947 | HYDROGEL-DRIVEN DRUG DOSAGE FORM - A controlled release dosage form has a coated core with the core comprising a drug-containing composition and a water-swellable composition, each occupying separate regions within the core. The drug-containing composition comprises a low-solubility drug and a drug-entraining agent. The coating around the core is water-permeable, water-insoluble and has at least one delivery port therethrough. A variety of formulations having specific drug release profiles are disclosed. | 07-28-2011 |
20110294902 | PHARMACEUTICAL COMPOSITIONS PROVIDING ENHANCED DRUG CONCENTRATIONS - A drug in a solubility-improved form is combined with a concentration-enhancing polymer in a sufficient amount so that the combination provides substantially enhanced drug concentration in a use environment relative to a control comprising the same amount of the same solubility-improved form of drug without the concentration-enhancing polymer. | 12-01-2011 |
20120003282 | PHARMACEUTICAL COMPOSITIONS OF DEXTRAN POLYMER DERIVATIVES - Pharmaceutical compositions are provided comprising an active agent and a dextran polymer derivative. The compositions include from 0.01 to 99 wt % of an active agent and from 1 to 99.99 wt % of a dextran polymer derivative. The dextran polymer derivative is selected from dextran acetate, dextran propionate, dextran succinate, dextran acetate propionate, dextran acetate succinate, dextran propionate succinate, dextran acetate propionate succinate, and mixtures thereof. | 01-05-2012 |
20120015924 | SPRAY-DRYING PROCESS - The process comprises delivering a spray solution comprising an active agent and a matrix material in an organic solvent to a spray-drying apparatus, atomizing the spray solution into droplets within the spray-drying apparatus to remove at least a portion of the organic solvent from the droplets to form a plurality of particles, and collecting the particles. The spray solution may be formed by forming a feed suspension comprising the active agent, the matrix material, and the organic solvent, wherein the feed suspension is at a temperature T | 01-19-2012 |
20120058196 | PHARMACEUTICAL COMPOSITIONS OF DEXTRAN POLYMER DERIVATIVES AND A CARRIER MATERIAL - Pharmaceutical compositions are provided comprising (a) nanoparticles of an active agent and a dextran polymer derivative, and (b) a carrier material. | 03-08-2012 |
20120259022 | PHARMACEUTICAL COMPOSITIONS PROVIDING ENHANCED DRUG CONCENTRATIONS - A drug in a solubility-improved form is combined with a concentration-enhancing polymer in a sufficient amount so that the combination provides substantially enhanced drug concentration in a use environment relative to a control comprising the same amount of the same solubility-improved form of drug without the concentration-enhancing polymer. | 10-11-2012 |
20120264833 | PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PERFORMANCE - Disclosed are polymers of hydroxypropyl methyl cellulose acetate succinate (HPMCAS) and hydroxypropyl methyl cellulose acetate (HPMCA) with unique degrees of substitution of hydroxypropoxy, methoxy, acetyl, and succinoyl groups. When used in making compositions comprising a low-solubility drug and such polymers, the polymers provide enhanced aqueous concentrations and/or improved physical stability. | 10-18-2012 |
20120277315 | PHARMACEUTICAL COMPOSITIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS - A pharmaceutical composition comprises a solid amorphous dispersion of a cholesteryl ester transfer protein inhibitor and a concentration-enhancing polymer. | 11-01-2012 |
20120295988 | Pharmaceutical Compositions of Dispersions of Amorphous Drugs Mixed with Polymers - A pharmaceutical composition comprises a dispersion comprising a low-solubility drug and a matrix combined with a concentration-enhancing polymer. At least a major portion of the drug is amorphous in the dispersion. The compositions improve the stability of the drug in the dispersion, and/or the concentration of drug in a use environment. | 11-22-2012 |
20120322805 | PHARMACEUTICAL COMPOSITIONS OF SEMI-ORDERED DRUGS AND POLYMERS - A solid composition of a low-solubility drug and a concentration-enhancing polymer has a portion of the drug in a semi-ordered state. | 12-20-2012 |
20130029965 | PHARMACEUTICAL SOLID DISPERSIONS - A composition comprises a solid dispersion comprising a low-solubility drug and at least one polymer. In another aspect of the invention, a composition comprises a solid dispersion comprising a low-solubility drug and a stabilizing polymer. At least a major portion of the drug in the dispersion is amorphous. The composition also includes a concentration-enhancing polymer that increases the concentration of the drug in a use environment. The stabilizing polymer has a glass transition temperature that is greater than the glass transition temperature of the concentration-enhancing polymer at a relative humidity of 50%. | 01-31-2013 |
20130102691 | HYDROXYPROPYL METHYL CELLULOSE ACETATE SUCCINATE WITH ENHANCED ACETATE AND SUCCINATE SUBSTITUTION - Disclosed are polymers of hydroxypropyl methyl cellulose acetate succinate (HPMCAS) with unique degrees of substitution of hydroxypropoxy, methoxy, acetyl, and succinoyl groups. When used in making compositions comprising a low-solubility active agent and such polymers, the polymers provide increased aqueous concentrations and/or improved physical stability of the active agent. | 04-25-2013 |
20130165371 | SPRAY-DRYING APPARATUS AND METHODS OF USING THE SAME - A spray-drying apparatus includes a drying chamber that has a first end, a second end, and at least one side wall extending between the first and second ends to define an interior of the drying chamber having a center axis. A nozzle can be positioned at the first end of the drying chamber and be configured to atomize liquid and spray the atomized liquid into the interior of the drying chamber at a maximum spray pattern angle relative to the center axis. A heating device can be provided to heat the liquid prior to introduction into the drying chamber. | 06-27-2013 |
20130193598 | HIGH-TEMPERATURE SPRAY DRYING PROCESS AND APPARATUS - The process comprises delivering a spray solution comprising at least one solute in a solvent to a spray-drying apparatus, using a flash nozzle to atomize the spray solution into droplets within the spray-drying apparatus to remove at least a portion of the solvent from the droplets to form a plurality of particles, and collecting the particles. The spray solution is directed to a heat exchanger, thereby increasing the temperature of the spray solution to a temperature T | 08-01-2013 |
20130345236 | PHARMACEUTICAL COMPOSITIONS PROVIDING ENHANCED DRUG CONCENTRATIONS - A drug in a solubility-improved form is combined with a concentration-enhancing polymer in a sufficient amount so that the combination provides substantially enhanced drug concentration in a use environment relative to a control comprising the same amount of the same solubility-improved form of drug without the concentration-enhancing polymer. | 12-26-2013 |
20140161895 | PHARMACEUTICAL COMPOSITIONS OF DEXTRAN POLYMER DERIVATIVES - Pharmaceutical compositions are provided comprising an active agent and a dextran polymer derivative. The compositions include from 0.01 to 99 wt % of an active agent and from 1 to 99.99 wt % of a dextran polymer derivative. The dextran polymer derivative is selected from dextran acetate, dextran propionate, dextran succinate, dextran acetate propionate, dextran acetate succinate, dextran propionate succinate, dextran acetate propionate succinate, and mixtures thereof. | 06-12-2014 |
20140171441 | PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PERFORMANCE - Pharmaceutical compositions of a low-solubility drug and lower alkanoate-, phthalate- and trimellitate esters of hydroxypropyl methyl cellulose and lower alkanoate- and succinate esters of cellulose and methyl cellulose are disclosed that provide enhanced concentrations of the drug in a use environment. | 06-19-2014 |
20140210117 | PHARMACEUTICAL COMPOSITIONS OF DISPERSIONS OF DRUG AND NEUTRAL POLYMERS - In one aspect, pharmaceutical compositions comprising dispersions of an acid-sensitive drug and a neutral dispersion polymer are disclosed. The acid-sensitive drug has improved chemical stability relative to dispersions of the drug and acidic polymers. In another aspect, pharmaceutical compositions of low-solubility drugs and amphiphilic, hydroxy-functional vinyl copolymers are disclosed. | 07-31-2014 |
20140322325 | PHARMACEUTICAL COMPOSITIONS PROVIDING ENHANCED DRUG CONCENTRATIONS - A drug in a solubility-improved form is combined with a concentration-enhancing polymer in a sufficient amount so that the combination provides substantially enhanced drug concentration in a use environment relative to a control comprising the same amount of the same solubility-improved form of drug without the concentration-enhancing polymer. | 10-30-2014 |
20150064264 | PHARMACEUTICAL DOSAGE FORMS COMPRISING A LOW-SOLUBILITY DRUG AND A POLYMER - A dosage form comprises a low-solubility drug, and a precipitation-inhibiting polymer. The drug is in a solubility-improved form and in the form of particles at least partially coated with the precipitation-inhibiting polymer. | 03-05-2015 |